Fredag 4 Juli | 09:31:11 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2026-02-11 07:00 Bokslutskommuniké 2025
2025-10-29 07:00 Kvartalsrapport 2025-Q3
2025-08-27 07:00 Kvartalsrapport 2025-Q2
2025-05-22 - X-dag ordinarie utdelning IRLAB A 0.00 SEK
2025-05-21 - Årsstämma
2025-05-07 - Kvartalsrapport 2025-Q1
2025-02-12 - Bokslutskommuniké 2024
2024-10-30 - Kvartalsrapport 2024-Q3
2024-07-10 - Kvartalsrapport 2024-Q2
2024-05-23 - X-dag ordinarie utdelning IRLAB A 0.00 SEK
2024-05-22 - Årsstämma
2024-05-08 - Kvartalsrapport 2024-Q1
2024-02-07 - Bokslutskommuniké 2023
2023-10-25 - Kvartalsrapport 2023-Q3
2023-08-30 - Kvartalsrapport 2023-Q2
2023-06-21 - X-dag ordinarie utdelning IRLAB A 0.00 SEK
2023-06-20 - Årsstämma
2023-05-10 - Kvartalsrapport 2023-Q1
2023-02-23 - Bokslutskommuniké 2022
2022-11-09 - Kvartalsrapport 2022-Q3
2022-08-24 - Kvartalsrapport 2022-Q2
2022-05-12 - X-dag ordinarie utdelning IRLAB A 0.00 SEK
2022-05-11 - Årsstämma
2022-05-11 - Kvartalsrapport 2022-Q1
2022-02-23 - Bokslutskommuniké 2021
2021-11-10 - Kvartalsrapport 2021-Q3
2021-08-25 - Kvartalsrapport 2021-Q2
2021-05-07 - X-dag ordinarie utdelning IRLAB A 0.00 SEK
2021-05-06 - Årsstämma
2021-05-06 - Kvartalsrapport 2021-Q1
2021-02-24 - Bokslutskommuniké 2020
2020-11-11 - Kvartalsrapport 2020-Q3
2020-08-26 - Kvartalsrapport 2020-Q2
2020-05-08 - X-dag ordinarie utdelning IRLAB A 0.00 SEK
2020-05-07 - Årsstämma
2020-05-07 - Kvartalsrapport 2020-Q1
2020-02-06 - Bokslutskommuniké 2019
2019-11-07 - Kvartalsrapport 2019-Q3
2019-08-28 - Kvartalsrapport 2019-Q2
2019-05-28 - Split IRLAB A 1:5
2019-04-26 - X-dag ordinarie utdelning IRLAB A 0.00 SEK
2019-04-25 - Årsstämma
2019-04-25 - Kvartalsrapport 2019-Q1
2019-02-27 - Bokslutskommuniké 2018
2018-11-14 - Kvartalsrapport 2018-Q3
2018-08-29 - Kvartalsrapport 2018-Q2
2018-05-17 - X-dag ordinarie utdelning IRLAB A 0.00 SEK
2018-05-16 - Årsstämma
2018-05-16 - Kvartalsrapport 2018-Q1
2018-02-27 - Bokslutskommuniké 2017
2017-11-15 - Kvartalsrapport 2017-Q3
2017-08-29 - Kvartalsrapport 2017-Q2
2017-05-16 - Årsstämma
2017-05-16 - Kvartalsrapport 2017-Q1
2017-02-27 - Bokslutskommuniké 2016

Beskrivning

LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriBioteknik
IRLAB Therapeutics är ett svenskt forsknings- och läkemedelsbolag. Forskningen utgår ifrån bolagets egna forskningsplattform och är specialiserad mot behandling av hjärnsjukdomar, vanligen benämnt neurodegenerativa sjukdomar. I nuvarande stund har bolaget läkemedelskandidater specialiserade mot bland annat Parkinsons sjukdom. Huvudkontoret ligger i Göteborg.
2025-07-03 07:00:00

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEELAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, RUSSIA, OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL REGISTRATION OR OTHER MEASURES. PLEASE REFER TO “IMPORTANT INFORMATION” IN THE END OF THIS PRESS RELEASE.

Today, on 3 July 2025, the subscription period commences in IRLAB Therapeutics AB’s (“IRLAB” or the “Company”) rights issue of shares of series A with preferential rights for existing shareholders up to approximately MSEK 136 (the “Rights Issue”), which was resolved and announced on 24 June 2025. The subscription period for the Rights Issue will run until and including 17 July 2025. However, please note that certain banks and nominees may apply an earlier deadline for subscription. Shareholders are therefore advised to check with their bank or nominee regarding any earlier response deadline that may apply.

Summary of the Rights Issue

  • The Rights Issue comprises a maximum of 38,901,304 shares of series A.
  • Upon full subscription, IRLAB will receive approximately MSEK 136 before deduction of issue-related costs.
  • The subscription price is SEK 3.50 per share.
  • The Rights Issue is covered by subscription undertakings amounting to approximately 33 percent, corresponding to approximately MSEK 44. The Company has furthermore entered into agreements on guarantee undertakings which amounts to a total of approximately MSEK 71, corresponding to approximately 52 percent of the Rights Issue.
  • In total, approximately 85 percent of the Rights Issue is thus secured by subscription and guarantee undertakings.
  • Anyone who was registered in the share register as a shareholder in IRLAB on the record date of 1 July 2025 received one (1) subscription right for each (1) share held, regardless of share series.
  • Four (4) subscription rights entitle for subscription of three (3) newly issued shares of series A.
  • Shareholders who choose not to participate in the Rights Issue will have their ownership diluted by up to approximately 42.9 percent but will have the opportunity to compensate themselves financially for the dilution effect by selling their subscription rights.
  • Full terms and conditions for the Rights Issue and other information about the Company are set out in the appendix IX information document published by the Company on 2 July 2025.

The information document and other information about the Rights Issue is available on the Company’s and Eminova Fondkommission AB’s respective websites, www.irlab.se and www.eminova.se.

Indicative time plan

The following time plan for the Rights Issue is preliminary and subject to change.

Trading in subscription rights3 July 2025 – 14 July 2025
Subscription period3 July 2025 – 17 July 2025
Trading in paid subscribed shares (BTA)3 July 2025 – week 31, 2025
Expected day for announcement of the outcome21 July 2025

Advisers

MAQS Advokatbyrå AB is legal advisor and Zonda Partners AB acts as financial advisor to the Company in connection with the Rights Issue.